Anti-Müllerian hormone (AMH) is one of the regulators of female reproductive physiology. AMH is mainly expressed by secondary follicles, pre-sinus and sinus follicle granulosa cells in fertile women, regulates follicular growth and development, and is not regulated by gonadotropins. It is used to evaluate the reserve function of the ovary, together with FSH, oestradiol, and inhibin B in early follicular phase. Ma, Fertility Center, Qilu Hospital, Shandong University, reported that AMH is a better predictor of ovarian reserve function than early follicular phase FSH, estradiol, and inhibin B. AMH levels are positively correlated with the number of eggs retrieved by women treated with ovulation induction therapy. Unlike other hormones that need to be monitored early in menstruation, AMH can be used to evaluate ovarian reserve function at any time. It has been reported that an AMH <14 pmol/l predicts a poor ovulation response (≤4 eggs). The serum AMH level in patients with polycystic ovary syndrome (PCOS) is 2-3 times higher than in women of the same age, and ovulation induction in PCOS patients is prone to ovarian hyperstimulation syndrome. It has been shown that with AMH >30 pmol/l, patients are at risk of developing ovarian hyperstimulation syndrome. Numerous studies have shown no correlation between serum AMH values and clinical pregnancy rates in ovulation induction cycles.